SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

SP0087

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Filed/Under Review (EU); Phase 3 completed (US pending submission)
Time to market
EU approval (European Commission decision) expected within weeks (by late November 2026). US BLA submission planned for 2H 2026, with FDA review likely extending into 2027.
Why 3/10
The next hard catalyst is the European Commission's final marketing authorization decision on VaxRabeo (SP0087), expected within approximately 67 days of the September 17, 2026 CHMP positive opinion (i.e., by late November 2026). Sanofi is a large-cap diversified pharma; this single vaccine is a small part of a 61-project pipeline, so even a positive EC decision will not materially move SNY's share price.
Actionable Insight NEUTRAL

The next hard catalyst is the European Commission's final decision on VaxRabeo (SP0087), expected within weeks after the September 17 CHMP positive opinion. A positive decision would enable EU launch and potentially accelerate Sanofi's US BLA submission, which was planned for 2H 2026. For a company of Sanofi's scale, this is a pipeline maintenance event rather than a stock-moving binary.

Price Chart

Loading chart...

Executive Summary

SP0087 is Sanofi's next-generation, serum-free, inactivated rabies vaccine (branded VaxRabeo in the EU). It completed Phase 3 trials showing non-inferior immunogenicity versus existing licensed rabies vaccines. On September 17, 2026, the EMA's CHMP adopted a positive opinion recommending EU marketing authorization for all age groups in both pre-exposure and post-exposure prophylaxis. The European Commission's final decision is expected within approximately 67 days (by late November 2026). Sanofi has also signaled intent to submit a US BLA in the second half of 2026. For a company of Sanofi's size and diversification, SP0087 is a modest pipeline asset in a roughly $1.4 billion global rabies vaccine market.

How It Works

SP0087 is an inactivated (killed-virus) rabies vaccine. It uses rabies virus grown in Vero cells (a standard cell line for vaccine production), then purified and inactivated so it cannot cause disease. When injected, it trains the immune system to produce antibodies against the rabies virus. It is formulated without serum (animal-derived components), which is a manufacturing improvement over older rabies vaccines. It is designed for both pre-exposure prevention (for travelers, lab workers) and post-exposure prophylaxis (after a potential rabies exposure, given alongside rabies immunoglobulin).

Trial Status

Multiple Phase 3 trials completed demonstrating non-inferior immunogenicity and safety versus licensed rabies vaccines (Verorab, Imovax, HDCV). The pivotal Phase 3 study (NCT04127786) read out positively in mid-2025. EU marketing application was filed in April 2026 and received a positive CHMP opinion on September 17, 2026.

The Two-Sided Case

▲ Bull Case4
SP0087 (VaxRabeo) received a positive CHMP opinion on September 17, 2026, with the European Commission expected to grant marketing authorization across all EU member states, covering all age groups for both pre- and post-exposure prophylaxis.
Phase 3 trials demonstrated non-inferior immunogenicity versus licensed rabies vaccines, and the serum-free formulation represents a manufacturing advancement over Sanofi's current Verorab product.
Sanofi has signaled intent to submit a US BLA in 2H 2026, opening the world's largest vaccines market; the global rabies vaccine market is projected to grow at roughly 5% CAGR to $1.79 billion by 2031.
Sanofi already dominates the rabies vaccine space with Verorab and Imovax, giving it established manufacturing, distribution, and WHO-prequalification infrastructure for SP0087.
▼ Bear Case4
As a next-generation version of Sanofi's own existing rabies vaccines (Verorab, Imovax), SP0087 may cannibalize the company's current rabies franchise rather than add entirely new revenue.
The global rabies vaccine market is modest at roughly $1.4 billion in 2026, limiting the commercial upside for any single new entrant.
Sanofi has not yet submitted a US BLA filing as of late October 2026 (planned for 2H 2026), meaning US approval is likely 12+ months away, delaying meaningful revenue.
Sanofi's existing rabies vaccines already compete with GSK, Merck, and multiple regional players; SP0087 enters a moderately concentrated market.

Upcoming Catalysts

  • European Commission final marketing authorization decision on VaxRabeo (SP0087), expected by late November 2026
  • Potential US BLA submission to FDA, planned for 2H 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 12

Hover a chip for the title
1 gosset.ai2 ema.europa.eu3 ema.europa.eu4 adisinsight.springer.com5 insights.citeline.com6 medscape.com7 novapharmanews.com8 ca.investing.com9 sanofi.com10 academic.oup.com11 mordorintelligence.com12 sanofi.com